Innovent and IASO Bio enhance collaboration for cell therapy
2024-07-05
Biopharmaceutical company Innovent Biologics (OTCPK:IVBIY) and IASO Biotechnology enter agreement under which IASO will purchase Innovent’s (OTCPK:IVBIY) relevant rights of FUCASO under the original “BCMA CAR-T Cell Therapy Cooperation Agreement” at the agreed price and Innovent (OTCPK:IVBIY) will use the proceeds to acquire an 18% stake in IASO Bio. UnderContinue Reading